WASHINGTON, Feb 5 (Reuters) – U.S. President Donald Trump plans to unveil TrumpRx.gov on Thursday evening, a website meant to offer consumers access to discounted prescription medicines and a central pillar of the president’s efforts to lower drug prices in the U.S., the White House said.
Sixteen of the largest drugmakers from around the world have struck “most-favored nation” deals with the Trump administration to cut drug prices for Americans in exchange for exemptions from U.S. tariffs. Under those agreements they will lower prices to the government’s Medicaid program and – via TrumpRX – to cash-paying consumers.
Those deals include agreements with obesity drugmakers Eli Lilly and Novo Nordisk to slash the prices of popular GLP-1 weight‑loss drugs. The government has said these would reduce prices to between $149 and $350 a month on average for Americans.
White House spokeswoman Karoline Leavitt said in a post on X that the direct-to-consumer website would be “state of the art” and “will save millions of Americans money.”
How much consumers will save and exactly how the website will work are still uncertain.
U.S. patients currently pay far more for prescription medicines, often nearly three times more than in other developed nations, and Trump has been pressuring drugmakers to lower prices to levels paid abroad.
Other drugmakers that have signed the deals include Pfizer Inc., AstraZeneca, Merck and GSK.
(Reporting by Michael Erman in New Jersey; Additional reporting by Doina Chiacu and Katharine Jackson in Washington; Editing by Michelle Nichols and Andrea Ricci )
